Cost-effectiveness analysis finds avelumab maintenance is economically viable for advanced urothelial carcinoma, supporting its adoption in clinical practice.
Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland.
No takes yet. Share an insight, caveat, or question.
Critchlow et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: